<DOC>
	<DOCNO>NCT00003783</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug combine drug different way may kill cancer cell . PURPOSE : Phase II trial study effectiveness chemotherapy treat child high risk acute lymphocytic leukemia .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Children With Very High Risk Acute Lymphocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Determine feasibility administer new combination agent postinduction consolidation therapy child high risk acute lymphocytic leukemia ( VHR-ALL ) . II . Assess tolerance patient remission VHR-ALL postconsolidation therapy continuous intensification . OUTLINE : Patients receive induction therapy week 1-4 . This consist oral prednisone three time day day 1-28 ; vincristine IV day 1 , 8 , 15 , 22 ; daunorubicin IV day 8 , 15 , 22 ; asparaginase IM day 2 , 5 , 8 , 12 , 15 , 19 . Patients also receive methotrexate intrathecally ( IT ) day 1 8 . Patients CNS 2 3 disease also receive methotrexate IT day 15 22 . Patients achieve M2 bone marrow day 29 receive oral prednisone three time day day 29-42 ; vincristine IV daunorubicin IV 15 minute day 29 36 ; asparaginase IM day 29 , 32 , 36 , 39 . If bone marrow M3 day 29 M2 M3 day 43 , patient study . Patients proceed consolidation therapy week 5-25 . This consist high dose methotrexate IV 24 hour week 6 , 8 , 16 , 18 , follow leucovorin calcium IV orally every 6 hour 5 dos ; oral mercaptopurine week 6-9 16-19 ; cytarabine IV 6 hour follow idarubicin IV 15 minute 4 day ; filgrastim ( G-CSF ) subcutaneously ( SQ ) begin day 5 continue 10-14 day week 10 20 . Patients receive etoposide IV 1 hour follow cyclophosphamide IV 10 minute 5 day G-CSF SQ begin day 6 10-14 day week 13 23 . Methotrexate IT administer week 6 , 8 , 13 , 16 , 18 , 23 . Patients proceed continuous intensification therapy week 26-61 . Patients receive vincristine IV , daunorubicin IV , methotrexate IT day 1 , oral dexamethasone twice day day 1-7 week 26 , 32 , 38 , 44 , 50 , 56 . Patients also receive high dose cytarabine IV 1 hour , every 12 hour , 4 dos , follow asparaginase IM 3 hour last dose cytarabine , week 27 , 33 , 39 , 45 , 51 , 57 . Oral mercaptopurine methotrexate IM administer day 1 week 29 , 31 , 35 , 37 , 41 , 43 , 47 , 49 , 53 , 55 , 59 , 61 . Patients receive etoposide IV 1-2 hour follow cyclophosphamide IV week 30 , 36 , 42 , 48 , 54 , 60 . Patients proceed continuation therapy week 62-126 . Vincristine IV cyclophosphamide IV administer week 62-65 , 70-73 , 78-81 , 86-89 , 94-97 , 102-105 , 110-113 , 118-121 . Patients also receive oral dexamethasone twice day 7 day week 62 , 70 , 78 , 86 , 94 , 102 , 110 , 118 , cytarabine IV week 63 , 65 , 71 , 73 , 79 , 81 , 87 , 89 , 95 , 97 , 103 , 105 , 111 , 113 , 119 , 121 . Oral mercaptopurine administer daily week 66-69 , 74-77 , 82-85 , 90-93 , 98-101 , 106-109 , 114-117 , 122-125 methotrexate IM week 66-69 , 74-77 , 82-85 , 90-93 , 98-101 , 106-109 , 114-117 , 122-125 . Methotrexate IT administer week 62 , 70 , 78 , 86 , 94 , 102 , 110 , 118 . Patients CNS 3 diagnosis receive whole brain irradiation begin week 62 along first course continuation therapy . These patient receive methotrexate IT week 62 . Patients follow monthly 1 year , every 2 month 1 year , every 3 month 1 year , every 6 month 1 year , annually thereafter . PROJECTED ACCRUAL : A total 38 patient accrue study within 12 month .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Newly diagnose Bcell precursor acute lymphocytic leukemia No L3 morphology Very poor prognosis CNS 3 ( blast WBC great 5 microliters ) OR Must meet following criterion : No simultaneous trisomy 4 10 DNA index great 1.16 ( FISH 4 10 unsatisfactory ) No TELAML1 [ ( 12 ; 21 ) ] Meets least 1 follow : Has MLL ( 11q23 ) and/or BCRABL [ ( 9 ; 22 ) ] WBC great 100,000/mm3 Age 12 ( boy ) 16 ( girl ) OR Boys Girls WBC 8 12 great 80,000/mm3 9 13 great 60,000/mm3 10 14 great 40,000/mm3 11 15 great 20,000/mm3 Concurrent registration stratum 6 POG9400 11/15/1999 OR Concurrent registration stratum 4 POG9900 11/15/1999 Concurrent registration POG9201 , POG9705 , POG9806 unless ineligible PATIENT CHARACTERISTICS : Age : Children Performance status : Not specify Life expectancy : Not specify Hematopoietic : See Disease Characteristics Hepatic : Not specify Renal : Not specify PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>untreated childhood acute lymphoblastic leukemia</keyword>
	<keyword>L1 childhood acute lymphoblastic leukemia</keyword>
	<keyword>L2 childhood acute lymphoblastic leukemia</keyword>
	<keyword>B-cell childhood acute lymphoblastic leukemia</keyword>
</DOC>